Friday 5-16-2014 Bristol-Myers Squibb Company (BMY
Post# of 115
Posted On: 05/17/2014 12:29:13 PM
Friday 5-16-2014 Bristol-Myers Squibb Company (BMY) $BMY opened at 49.06 hitting the high price of 49.18 and a day low of 48.58 with a total volume of 11,151,300. BMY had a previous close of 48.93 and has been seeing an average volume of 8,865,665.
Overall Average: 96% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards
PR Newswire - Fri May 16, 1:43PM CDT
TogoRun (www.togorun.com), a global health and well-being communications and public affairs agency, was named International Agency of the Year at the inaugural PRWeek Global Awards ceremony last night in Barcelona, Spain. The agency was also named winner in the Corporate Social Responsibility category for PATH B (Patients and Professionals Acting Together for Hepatitis
, a hepatitis B patient and professional engagement and education program developed for Bristol-Myers Squibb. (full story)
ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies... (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.
George Budwell, The Motley Fool - Motley Fool - Fri May 16, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Shares of Bristol-Myers Squibb fell over 6% yesterday following a downgrade by BMO Capital Markets after the company reported weak... (full story)
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Business Wire - Fri May 16, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT (7 a.m. CDT) to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the company's immuno-oncology portfolio, and address inquiries from investors and analysts. (full story)
Why the National Bank of Greece, Alliant Techsystems Inc., and Bristol-Myers Squibb Co Are Today's 3
Dan Carroll, The Motley Fool - Motley Fool - Thu May 15, 6:00PM CDT
Where'd the gains go? That's what investors were left asking themselves after today's market plunge. The S&P 500 nosedived by 0.9% on a day marked by red across most industries. Three stocks suffered steep downturns, however, as the National... (full story)
Bristol-Myers downgraded
at Investor's Business Daily - Thu May 15, 5:39PM CDT
The big pharma was downgraded to market perform from outperform by BMO Capital Markets. Its price target was cut to 55 from 65 after phase-2 data on Bristol- Myers' (BMY) immuno-oncology candidate was released Wed. The drug, nivolumab, is used in... (full story)
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors... (full story)
Most active New York Stock Exchange-traded stocks
AP - Thu May 15, 5:15PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study. (full story)
Wal-Mart and Kohl's are big market movers
AP - Thu May 15, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising... (full story)
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen. (full story)
Bristol-Myers slumps on cancer drug study data
AP - Thu May 15, 12:32PM CDT
NEW YORK (AP) — Shares of Bristol-Myers Squibb slumped Thursday after the drugmaker reported disappointing clinical trial data for an experimental cancer treatment. (full story)
NYSE stocks posting largest percentage decreases
AP - Thu May 15, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.: (full story)
Overall Average: 96% Sell
Recent stock forum discussions about BMY http://investorshangout.com/search?q=BMY&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards
PR Newswire - Fri May 16, 1:43PM CDT
TogoRun (www.togorun.com), a global health and well-being communications and public affairs agency, was named International Agency of the Year at the inaugural PRWeek Global Awards ceremony last night in Barcelona, Spain. The agency was also named winner in the Corporate Social Responsibility category for PATH B (Patients and Professionals Acting Together for Hepatitis
, a hepatitis B patient and professional engagement and education program developed for Bristol-Myers Squibb. (full story) ASCO 2014: Making and Breaking Cancer Drugs
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri May 16, 1:30PM CDT
As oncology has become the hottest space within pharmaceuticals and biotech, the annual American Society of Clinical Oncology (ASCO) is pretty much now the Super Bowl for companies in this space. Meetings like ASCO certainly do lead to companies... (full story)
Midday Glance: Pharmaceuticals companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Early Glance: Pharmaceuticals companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.
George Budwell, The Motley Fool - Motley Fool - Fri May 16, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Shares of Bristol-Myers Squibb fell over 6% yesterday following a downgrade by BMO Capital Markets after the company reported weak... (full story)
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Business Wire - Fri May 16, 7:00AM CDT
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT (7 a.m. CDT) to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the company's immuno-oncology portfolio, and address inquiries from investors and analysts. (full story)
Why the National Bank of Greece, Alliant Techsystems Inc., and Bristol-Myers Squibb Co Are Today's 3
Dan Carroll, The Motley Fool - Motley Fool - Thu May 15, 6:00PM CDT
Where'd the gains go? That's what investors were left asking themselves after today's market plunge. The S&P 500 nosedived by 0.9% on a day marked by red across most industries. Three stocks suffered steep downturns, however, as the National... (full story)
Bristol-Myers downgraded
at Investor's Business Daily - Thu May 15, 5:39PM CDT
The big pharma was downgraded to market perform from outperform by BMO Capital Markets. Its price target was cut to 55 from 65 after phase-2 data on Bristol- Myers' (BMY) immuno-oncology candidate was released Wed. The drug, nivolumab, is used in... (full story)
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors... (full story)
Most active New York Stock Exchange-traded stocks
AP - Thu May 15, 5:15PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study. (full story)
Wal-Mart and Kohl's are big market movers
AP - Thu May 15, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
Could Bristol-Myers End Up Acquiring Celldex?
Todd Campbell, The Motley Fool - Motley Fool - Thu May 15, 1:30PM CDT
Celldex 's shares jumped by more than a quarter following news that Bristol-Myers has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising... (full story)
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen. (full story)
Bristol-Myers slumps on cancer drug study data
AP - Thu May 15, 12:32PM CDT
NEW YORK (AP) — Shares of Bristol-Myers Squibb slumped Thursday after the drugmaker reported disappointing clinical trial data for an experimental cancer treatment. (full story)
NYSE stocks posting largest percentage decreases
AP - Thu May 15, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.: (full story)
(0)
(0)Bristol-Myers Squibb Company (BMY) Stock Research Links
Scroll down for more posts ▼